Immunization

Investigators analyze to see if there was an association of expected benefits and risk of vaccination.

The company announced the initiation of the EVERGREEN study, which was aimed to evaluate the efficacy, safety, and immunogenicity of the investigational respiratory syncytial virus vaccine, in 2021.

The pandemic was eye-opening for many pharmacists, and one expert reflects on recognizing the importance of the pharmacy technician and accessible healthcare.

Imminent March, April expiration dates indicate changes are on the horizon for pharmacy services.

Michael D. Hogue, PharmD, FAPhA, FNAP, FFIP, discusses current outlook on the occurrence of outbreaks of vaccine-preventable diseases in the country.

Services include adherence assessments, health screenings, medication reconciliation, vaccine administration.

Investigators estimate that the effectiveness was higher after 1 or 2 booster doses compared with the primary series alone.

Findings from the ongoing Adult Respiratory Syncytial Virus phase 3 trial suggest RSVPreF3 OA vaccine is effective and safe for individuals aged 60 years and older.

Further research is needed across countries and health systems about PCV13, according to the systematic review published in Taylor & Francis Online.

Staff members, especially immunizers, should look at every encounter as an opportunity to educate, support patients.

MenABCWY combination meets all 11 primary endpoints and shows that it is well tolerated, with a safety profile consistent with MenACWY (Menveo) and MenB (Bexsero).

Among the participants who were initially unsure or hesitant about vaccination, 82% received flu and Tdap vaccines during pregnancy after the online intervention.

This episode features Bruce Berger, PhD, president of Berger Consulting, LLC, who discusses how pharmacists should best use motivational interviewing with patients.

The fourth dose of the bivalent vaccine elicited improved Omicron BA.4/BA.5-neutralizing antibody responses compared to participants who received 3 doses of the original vaccine.

Vaccination rates were significantly higher in study groups who received a letter highlighting the potential cardiovascular benefits of vaccination and who received repeat letters about the importance of flu vaccination in general.

Due to the success of mRNA technology with COVID-19, there has been a significant increase in research looking into utilizing mRNA technology, and more specifically, how it can help to advance vaccine development.

The FDA set a Prescription Drug User Fee Act for May 2023 for Pfizer’s respiratory syncytial virus bivalent vaccine candidate.

Companies seek FDA approval for individuals aged 12 years and older to receive vaccinations for their primary series.

Phase 3 trial results indicate efficacy against respiratory syncytial virus-lower respiratory tract disease in individuals aged 60 years and older.

Ideally, older patients receive vaccinations by October, but disease activity often peaks in February or March.

If approved, the vaccine would be the first immunization for use in pregnant individuals to help protect against the complications of respiratory syncytial virus in infants from birth through 6 months.

With recent outbreaks of measles and other vaccine-preventable diseases, vaccinations are more important than ever.

One of the major concerns about getting a flu vaccine is its safety for women during pregnancy.

Approximately 48.1% of those who received vaccines had family members or friends who were either sick or recovered from the illness compared with 26.9% who were unvaccinated.

Antibodies from an original COVID-19 vaccination may treat the mRNA booster vaccine as a virus that needs to be cleared.